April 10, 2007 - DocuSys Inc., a provider of Anesthesia Information Systems (AIS) and Digital Drug Management Systems, announced the release of its second generation DocuJect, a point-of-care safety device for monitoring drug deliveries in the OR environment.

The announcement comes on the heels of the release of a widely publicized new study by the U.S. Pharmacopeia revealing that 5 percent of perioperative errors result in harm and that drug dose (particularly in pediatric patients) and communication errors were common causes of these errors. The study found that surgery patients are three times more likely to experience a harmful medication error than patients anywhere else in the health care system, prompting the following comment from one of the study's authors, Peter Pronovost, M.D., Ph.D., who is familiar with the DocuJect product. "Among other strategies, technologies like DocuJect that automate drug delivery hold promise to reduce these harmful events."

DocuJect combines digital imaging and bar code scanning technologies to enable instant interaction with patient and drug databases to provide alerts to the clinician before an impending adverse drug reaction or medication error can occur. The device also automates documentation of drug delivery in real- time. Installation of DocuJect II in DocuSys hospitals will begin in April.


Related Content

News | Image Guided Radiation Therapy (IGRT)

June 7, 2022 — Two-year results from the Dysphagia-Aspiration Related Structures (DARS) trial, which is funded by Cancer ...

Time June 07, 2022
arrow
News | Image Guided Radiation Therapy (IGRT)

May 19, 2022 — Brainlab announced that clinicians at UZ Brussel are the first to treat patients with the company’s new ...

Time May 19, 2022
arrow
News | Radiation Oncology

August 27, 2021 — For decades, the National Comprehensive Cancer Network (NCCN) recommended forgoing post-lumpectomy ...

Time August 27, 2021
arrow
News | Radiation Therapy

June 10, 2020 — A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides ...

Time June 10, 2020
arrow
News | Radiation Therapy

April 16, 2020 — RefleXion Medical, a therapeutic oncology company pioneering the use of biology-guided radiotherapy ...

Time April 16, 2020
arrow
News | Image Guided Radiation Therapy (IGRT)

February 11, 2020 — Varian announced it has received FDA 510(k) clearance for its Ethos therapy, an Adaptive ...

Time February 11, 2020
arrow
News | Radiology Imaging

December 12, 2019 — Philips and the Regional Medical Center (RMC) announced a strategic 5-year partnership agreement ...

Time December 12, 2019
arrow
News | Radiation Therapy

October 22, 2019 — The American Society for Radiation Oncology (ASTRO) and the American College of Radiology (ACR) ...

Time October 22, 2019
arrow
News | Image Guided Radiation Therapy (IGRT)

ViewRay Inc. announced today that patient treatments are scheduled to begin in Boston with ViewRay's MRIdian Linac System at Dana-Farber/Brigham and Women's Cancer Center. The MRIdian provides for the delivery of radiation therapy to targeted tumors while simultaneously providing continuous magnetic resonance imaging (MRI).

Time October 08, 2019
arrow
News | Image Guided Radiation Therapy (IGRT)

At the 2019 American Society for Radiation Oncology (ASTRO) annual meeting, being held Sept. 15-18 in Chicago, Varian announced Ethos therapy, an artificial intelligence (AI)-driven holistic solution designed to increase the capability, flexibility and efficiency of radiotherapy. This new solution is designed to deliver an entire adaptive treatment in a typical 15-minute timeslot, from patient setup through treatment delivery.

Time September 16, 2019
arrow
Subscribe Now